Katherine Stueland Sells 18,006 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 18,006 shares of the business’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $78.18, for a total value of $1,407,709.08. Following the completion of the transaction, the chief executive officer now owns 53,140 shares in the company, valued at approximately $4,154,485.20. This trade represents a 25.31 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Katherine Stueland also recently made the following trade(s):

• On Monday, December 16th, Katherine Stueland sold 10,501 shares of GeneDx stock. The shares were sold at an average price of $76.75, for a total value of $805,951.75.
• On Monday, December 9th, Katherine Stueland sold 3,661 shares of GeneDx stock. The stock was sold at an average price of $76.37, for a total transaction of $279,590.57.
• On Monday, November 18th, Katherine Stueland sold 22,307 shares of GeneDx stock. The shares were sold at an average price of $70.34, for a total transaction of $1,569,074.38.
• On Friday, November 15th, Katherine Stueland sold 23,108 shares of GeneDx stock. The shares were sold at an average price of $70.48, for a total transaction of $1,628,651.84.
• On Tuesday, October 29th, Katherine Stueland sold 2,154 shares of GeneDx stock. The shares were sold at an average price of $66.60, for a total value of $143,456.40.

GeneDx Stock Down 0.5 %

WGS stock opened at $96.57 on Thursday. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25. The firm’s 50-day simple moving average is $77.48 and its 200 day simple moving average is $52.46. The stock has a market cap of $2.65 billion, a PE ratio of -31.05 and a beta of 2.02. GeneDx Holdings Corp. has a fifty-two week low of $2.85 and a fifty-two week high of $98.87.

GeneDx (NASDAQ:WGS) last released its quarterly earnings results on Tuesday, October 29th. The company reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.25. GeneDx had a negative return on equity of 13.35% and a negative net margin of 31.25%. The company had revenue of $76.90 million for the quarter, compared to analysts’ expectations of $64.98 million. During the same quarter in the previous year, the company posted ($0.82) earnings per share. The business’s revenue for the quarter was up 44.3% compared to the same quarter last year. As a group, sell-side analysts predict that GeneDx Holdings Corp. will post -0.24 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently commented on WGS shares. Wells Fargo & Company lifted their target price on GeneDx from $34.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 30th. TD Cowen boosted their target price on shares of GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a research note on Tuesday. The Goldman Sachs Group raised their price target on shares of GeneDx from $54.00 to $70.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 30th. Finally, Craig Hallum boosted their price objective on shares of GeneDx from $70.00 to $95.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $70.67.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Acadian Asset Management LLC acquired a new position in shares of GeneDx during the second quarter valued at approximately $34,000. CWM LLC acquired a new position in shares of GeneDx during the 3rd quarter valued at $89,000. SG Americas Securities LLC bought a new stake in shares of GeneDx in the 3rd quarter worth $198,000. Point72 DIFC Ltd acquired a new stake in shares of GeneDx in the third quarter valued at $220,000. Finally, Palumbo Wealth Management LLC bought a new position in GeneDx during the third quarter valued at about $287,000. Institutional investors own 61.72% of the company’s stock.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.